Review of the Results of Previous Phase II, Magnetic Resonance Imaging-monitored Clinical Trials

  • P. Soelberg Sørensen
Conference paper
Part of the Topics in Neuroscience book series (TOPNEURO)


During the last decade magnetic resonance imaging(MRI) has become a useful tool for monitoring efficacy of new treatments in multiple sclerosis (MS). Serial MRI detects 10 times more disease activity than does the registration of clinical relapses in patients with relapsing-remitting MS or in the early phase of secondary progressive MS.[1, 2]. Consequently, MRI is a sensitive tool for monitoring therapeutically induced changes in disease activity which can be measured objectively and quantitatively compared to the subjective evaluation of clinical changes.


Magnetic Resonance Imaging Multiple Sclerosis Expanded Disability Status Scale Active Lesion Expanded Disability Status Scale Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller DH, Barkhof F, Berry I, et al. (1991) Magnetic resonance imaging in monitoring treatment of multiple sclerosis: Concerted action guidelines. J Neurol Neurosurg Psychiatry 54: 683–688PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Miller DH, Barkhof F, Nauta JJ (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116: 1077–1094PubMedCrossRefGoogle Scholar
  3. 3.
    Filippi M, Paty DW, Kappos L, et al. (1995) Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: A follow-up study. Neurology 45: 255–260PubMedCrossRefGoogle Scholar
  4. 4.
    Koudriavtseva T, Thompson AJ, Fiorelli M, et al. (1997) Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 62: 285–287PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Miller DH, Albert PS, Barkhof F, et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National multiple sclerosis Society Task Force. Ann Neurol 39: 6–16Google Scholar
  6. 6.
    Grossman RI, Gonzalez SF, Atlas SW, et al. (1986) Multiple sclerosis: Gadolinium enhancement in MR imaging. Radiology 161: 721–725PubMedCrossRefGoogle Scholar
  7. 7.
    Smith ME, Stone LA, Albert PS, et al. (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 33: 480–489PubMedCrossRefGoogle Scholar
  8. 8.
    Tubridy N, Coles AJ, Molyneux D, et al. (1998) Secondary progressive multiple sclerosis: The relationship between short-term MRI activity and clinical features. Brain 121: 225–231PubMedCrossRefGoogle Scholar
  9. 9.
    Filippi M, Campi A, Martinelli V, et al. (1995) A brain MRI study of different types of chronic-progressive multiple sclerosis. Acta Neurol Scand 91: 231–233PubMedCrossRefGoogle Scholar
  10. 10.
    Andersen 0, Lycke J, Tollesson PO, et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895–900PubMedCrossRefGoogle Scholar
  11. 11.
    Karussis DM, Meiner Z, Lehmann D, et al.(1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47: 341–346PubMedCrossRefGoogle Scholar
  12. 12.
    Edan G, Miller D, Clanet M, et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62: 112–118PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Pozzilli C, Bastianello S, Koudriavtseva T, et al. (1996) Magnetic resonance imaging changes with recombinant human interferon-beta-la: A short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61: 251–258PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Stone LA, Frank JA, Albert PS, et al. (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37: 611–619PubMedCrossRefGoogle Scholar
  15. 15.
    Stone LA, Frank JA, Albert PS, et al. (1997) Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49: 862–869PubMedCrossRefGoogle Scholar
  16. 16.
    The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661CrossRefGoogle Scholar
  17. 17.
    The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277–1285CrossRefGoogle Scholar
  18. 18.
    Paty DW, Li DKB (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB multiple sclerosis Study Group. Neurology 43: 662–667PubMedCrossRefGoogle Scholar
  19. 19.
    Sorensen PS, Wanscher B, Jensen CV, et al. (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273–1281PubMedCrossRefGoogle Scholar
  20. 20.
    Moreau T, Thorpe J, Miller D, et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 13,344: 298–301CrossRefGoogle Scholar
  21. 21.
    van Oosten BW, Lai M, Hodgkinson S, et al. (1997) Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49: 351–357PubMedCrossRefGoogle Scholar
  22. 22.
    Sorensen PS, Wanscher B, Szpirt W, et al. (1996) Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: A randomized single-masked cross-over pilot study. Neurology 46:1620–1625PubMedCrossRefGoogle Scholar
  23. 23.
    Oliveri RL, Valentino P, Russo C, et al. (1998) Randomized trial comparing two different high doses of methylprednisolone in multiple sclerosis: A clinical and MRI study. Neurology 50: 1833–1836PubMedCrossRefGoogle Scholar
  24. 24.
    Millefiorini E, Gasperini C, Pozzilli C, et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244: 153–159PubMedCrossRefGoogle Scholar
  25. 25.
    Bastianello S, Pozzilli C, D’Andrea F, et al. (1994) A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year. Can J Neurol Sci 21: 266–270PubMedGoogle Scholar
  26. 26.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37: 30–40PubMedCrossRefGoogle Scholar
  27. 27.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs. Neurology 47: 1153–1157PubMedCrossRefGoogle Scholar
  28. 28.
    Sipe JC, Romine JS, Koziol JA, et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344: 9–13PubMedCrossRefGoogle Scholar
  29. 29.
    Sipe JC, Romine JS, Koziol JA, et al. (1996) Development of cladribine treatment in multiple sclerosis. Mult Scler 1: 343–347PubMedGoogle Scholar
  30. 30.
    Zhao GJ, Li DKB, Wolinsky JS, et al. (1997) Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The multiple sclerosis Study Group. J Neuroimaging 7: 1–7PubMedGoogle Scholar
  31. 31.
    The Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 27: 591–605CrossRefGoogle Scholar
  32. 32.
    Durelli L, Bongioanni MR, Cavallo R, et al. (1994) Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44: 406–413PubMedCrossRefGoogle Scholar
  33. 33.
    Durelli L, Bongioanni MR, Cavallo R, et al. (1995) Interferon alpha treatment of relapsing-remitting multiple sclerosis: Long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function. Mult Scler l(Suppl 1): S32–S37Google Scholar
  34. 34.
    Kastrukoff LF, Oger JJ, Hashimoto SA, et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 40: 479–486PubMedCrossRefGoogle Scholar
  35. 35.
    Achiron A, Gabbay U, Gilad R, et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50: 398–402Google Scholar
  36. 36.
    Milligan NM, Miller DH, Compston DA (1994) A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 57: 164–168PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Wiles CM, Omar L, Swan AV, et al (1994) Total lymphoid irradiation in MS. J Neurol Neurosurg Psychiatry 57: 154–163PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Rumbach L, Racodot E, Armspach JP, et al. (1996) Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Mult Scler 1:207–212PubMedGoogle Scholar
  39. 39.
    van Oosten BW, Barkhof F, Truyen L, et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531–1534PubMedCrossRefGoogle Scholar
  40. 40.
    Calabresi PA, Fields NS, Maloni HW, et al. (1998) Phase 1 trial of transforming growth factor beta 2 in chronic progressive multiple sclerosis. Neurology 51: 289–292PubMedCrossRefGoogle Scholar
  41. 41.
    Fernandez O, Antiquedad A, Arbizu T, et al. (1995) Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Mult Scler 1 (Suppl 1): S67–S69PubMedGoogle Scholar
  42. 42.
    Nyland H, Myhr KM, Lillas F, et al. (1996) Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alpha-2a: design of a randomised, placebo-controlled, double blind trial in Norway. Mult Scler 1: 372–375PubMedGoogle Scholar
  43. 43.
    Kappos L, Radu EW, Bernasconi L, et al. (1993) Treatment of multiple sclerosis with 15 +/-deoxyspergualin. Design of a controlled study with close MRI-monitoring. Schweiz Arch Neurol Psychiatr 144:198–201PubMedGoogle Scholar
  44. 44.
    Harris JO, Frank JA, Patronas N, et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history. Ann Neurol 29: 548–555PubMedCrossRefGoogle Scholar
  45. 45.
    Stone LA, Smith ME, Albert PS, et al. (1995) Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology 45: 1122–1126PubMedCrossRefGoogle Scholar
  46. 46.
    Nauta JJ, Thompson AJ, Barkhof F, Miller DH (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallelgroups and crossover designs. J Neurol Sci 122: 6–14PubMedCrossRefGoogle Scholar
  47. 47.
    Miller DH, Grossman RI, Reingold SC, McFarland HF (1998) The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121: 3–24PubMedCrossRefGoogle Scholar
  48. 48.
    Molyneux PD, Filippi M, Barkhof F, et al. (1998) Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 43: 332–339PubMedCrossRefGoogle Scholar
  49. 49.
    Filippi M, Horsfield MA, Morrissey SP, et al. (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44: 635–641PubMedCrossRefGoogle Scholar
  50. 50.
    Koziol JA, Wagner S, Adams HP (1998) Assessing information in T2-weighted MRI scans from secondary progressive multiple sclerosis patients. Neurology 51: 228–233PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1999

Authors and Affiliations

  • P. Soelberg Sørensen
    • 1
  1. 1.MS Research Unit, The Neuroscience CenterCopenaghen University Hospital, RigshospitaletCopenaghenDenmark

Personalised recommendations